FTC to Investigate Prescription-Drug Middlemen and Drug Patents, Lina Khan States
Tuesday, 23 April 2024, 17:06
FTC's Swift Action:
The Federal Trade Commission, led by Chair Lina Khan, is intensifying its investigation into prescription-drug middlemen at an accelerated pace. This move is aimed at increasing transparency and accountability in the pharmaceutical sector.
Expanded Inquiry:
Chair Lina Khan stated that the FTC will also widen its examination to include a closer look at drug patents. This expansion signifies a more comprehensive approach to regulating the prescription-drug market.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.